Cleavage of aggrecan at the Asn341-Phe342 site coincides with the initiation of collagen damage in murine antigen-induced arthritis: a pivotal role for stromelysin 1 in matrix metalloproteinase activity.
OBJECTIVE
The destruction of articular cartilage during arthritis is due to proteolytic cleavage of the extracellular matrix components. This study investigates the kinetic involvement of metalloproteinases (MMPs) in the degradation of the 2 major cartilage components, aggrecan and type II collagen, during murine antigen-induced arthritis (AIA). In addition, the role of stromelysin 1 (SLN-1) induction of MMP-induced neoepitopes was studied.


METHODS
VDIPEN neoepitopes in aggrecan and collagenase-induced COL2-3/4C neoepitopes in type II collagen were identified by immunolocalization. Stromelysin 1-deficient knockout (SLN1-KO) mice were used to study SLN-1 involvement.


RESULTS
In AIA, the VDIPEN epitopes in aggrecan appeared after initial proteoglycan (PG) depletion. The collagenase-induced type II collagen neoepitopes colocalized with VDIPEN epitopes. Remarkably, cartilage from arthritic SLN1-KO mice showed neither the induction of VDIPEN nor collagen cleavage-site neoepitopes during AIA, suggesting that stromelysin is a pivotal mediator in this process. PG depletion, as measured by the loss of Safranin O staining, was similar in SLN1-KO mice and wild-type strains. Furthermore, in vitro induction of VDIPEN epitopes in aggrecan and COL2-3/4C epitopes in type II collagen, on exposure of cartilage to interleukin-1, could not be accomplished in SLN1-KO mice, whereas intense staining was achieved for both epitopes in cartilage of wild-type strains.


CONCLUSIONS
This study emphasizes that SLN-1 is essential in the induction of MMP-specific aggrecan and collagen cleavage sites during AIA. It suggests that SLN-1 is not a dominant enzyme in PG breakdown, but that it activates procollagenases and is crucial in the initiation of collagen damage.
van Meurs
J
J
University Hospital Nijmegen, The Netherlands.
van Lent
P
P
Stoop
R
R
Holthuysen
A
A
Singer
I
I
Bayne
E
E
Mudgett
J
J
Poole
R
R
Billinghurst
C
C
van der Kraan
P
P
Buma
P
P
van den Berg
W
W
D053674:Aggrecans; D000818:Animals; D000941:Antigens; D001168:Arthritis / Q000276:immunology / Q000378:metabolism* / Q000473:pathology; D002356:Cartilage / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D003094:Collagen / Q000235:genetics / Q000378:metabolism*; D000939:Epitopes / Q000235:genetics / Q000276:immunology / Q000378:metabolism; D005109:Extracellular Matrix / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D016326:Extracellular Matrix Proteins; D037181:Lectins, C-Type; D019278:Matrix Metalloproteinase 3 / Q000172:deficiency* / Q000235:genetics; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D009842:Oligopeptides / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D010446:Peptide Fragments / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D011509:Proteoglycans / Q000378:metabolism*
C508320:Acan protein, mouse; D053674:Aggrecans; D000941:Antigens; D000939:Epitopes; D016326:Extracellular Matrix Proteins; D037181:Lectins, C-Type; D009842:Oligopeptides; D010446:Peptide Fragments; D011509:Proteoglycans; C093378:peptide VDIPEN; D003094:Collagen; D019278:Matrix Metalloproteinase 3